- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2605541, Insulin glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 33
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 119
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 99
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin Degludec, Insulin Glargine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide (AC2993), Insulin glargine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 21
- States / cities
- San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 984 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
- Conditions
- Type 1 Diabetes, Dawn Phenomenon
- Interventions
- Lantus (glargine)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Interventions
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 24
- States / cities
- Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Temecula, California • Minneapolis, Minnesota • Portland, Oregon
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin degludec, Insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more
- Conditions
- Gestational Diabetes Mellitus, Pregnancy, High Risk
- Interventions
- Metformin, Insulin
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 26
- States / cities
- Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
- Conditions
- Diabetes Mellitus
- Interventions
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Poor Glycemic Control
- Interventions
- Metformin, Glargine insulin, Glulisine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Human Insulin Inhalation Powder, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 6
- States / cities
- Greenbrae, California • Topeka, Kansas • Toms River, New Jersey + 3 more
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 118
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SAR342434, Humalog, insulin glargine HOE901
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 51
- States / cities
- Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Insulin glargine U100
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 13
- States / cities
- Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 20
- States / cities
- Anaheim, California • Los Angeles, California • Miami, Florida + 15 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, Liraglutide, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 978 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Gan & Lee Insulin Glargine Injection, Lantus®
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more
- Conditions
- Diabetes Mellitus
- Interventions
- MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
- Drug · Device
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Diabetes Mellitus, Insulin-Dependent
- Interventions
- Insulin glulisine, insulin lispro, insulin glargine, NPH insulin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania